A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies
- 1 December 1984
- journal article
- research article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 150 (8) , 927-931
- https://doi.org/10.1016/0002-9378(84)90383-1
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- VP16-213, cisplatinum, and adriamycin salvage therapy of refractory and/or recurrent nonseminomatous germ cell neoplasmsCancer Chemotherapy and Pharmacology, 1982
- Alpha fetoprotein determinations in the management of endodermal sinus tumors and mixed germ cell tumors of the ovaryAmerican Journal of Obstetrics and Gynecology, 1981
- VP-16–213 salvage therapy for refractory germinal neoplasmsCancer, 1980
- Endodermal sinus tumor of the ovary: An improving prognosisGynecologic Oncology, 1980
- Therapy of endodermal sinus tumor of the ovaryAmerican Journal of Obstetrics and Gynecology, 1979
- Teratomas of the ovary.BMJ, 1979
- Malignant teratoma of the ovary: Prognostic factors and treatmentAmerican Journal of Obstetrics and Gynecology, 1978
- Serum alpha‐fetoprotein as a marker for the effect of post‐operative radiation therapy and/or chemotherapy in eight cases of ovarian endodermal sinus tumourInternational Journal of Cancer, 1976
- Advances in chemotherapy for gynecologic cancerCancer, 1975
- Alpha-fetoprotein and endodermal sinus tumor of the ovaryAmerican Journal of Obstetrics and Gynecology, 1973